Oocyte Vitrification Aided With Latrunculin A

N/ACompletedNCT03678571

Ibn Sina Hospital400 enrolled

Overview

Using cytoskeleton Stabilizer the Latrunculin A would improve the outcome of oocyte vitrification

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

TRIPLE

Enrollment

400

Conditions

Infertility

Interventions

Latrunculin A supplemented vitrification mediumOTHER

Vitrification of human oocyte in medium supplemented with Latrunculin A

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: * indication for oocyte cryopreservation Exclusion Criteria: \-

Locations (3)

Qena Fertility Center

Qina, Qena Governorate, Egypt

Banon Assiut

Asyut, Egypt

IbnSina IVF Center, IbnSina Hospital

Sohag, Egypt

Outcomes

Primary Outcomes

survival after thawing

Time frame: 6 days after thawing

Secondary Outcomes

fertilization rate

Time frame: 6 days of culture

Rates of blastocyst formation and quality

Number of formed blastocyst and high-quality blastocysts per fertilized oocytes

Time frame: 6 days of culture

embryo utilization rate

Number of utilized embryos per fertilized oocytes

Time frame: 6 days of culture

clinical pregnancy rate

Number of pregnant women with fetal pulsation per recruited cycles

Time frame: three months

ongoing pregnancy rate

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.